Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 158 | 14 | 142 |
| Samples | 154 | 14 | 138 |
| Peptides | 96 | 10 | 89 |
Function
IL27 · Interleukin 27
The protein encoded by this gene is one of the subunits of a heterodimeric cytokine complex. This protein is related to interleukin 12A (IL12A). It interacts with Epstein-Barr virus induced gene 3 (EBI3), a protein similar to interleukin 12B (IL12B), and forms a complex that has been shown to drive rapid expansion of naive but not memory CD4(+) T cells. The complex is also found to synergize strongly with interleukin 12 to trigger interferon gamma (IFNG) production of naive CD4(+) T cells. The biological effects of this cytokine are mediated by the class I cytokine receptor (WSX1/TCRR). [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000356897 | Q8NEV9 | 158 | 96 |
Gene Properties
Recurrent Mutations
All 96 amino-acid changes on canonical ENST00000356897 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IL27 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IL27 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Melanoma | 1/210 0% | 26/1899 1% |
| Endometrial Carcinoma | 0/42 0% | 5/612 1% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 11/1390 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 6/810 1% |
| Colorectal Carcinoma | 3/143 2% | 20/3239 1% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Gastric Carcinoma | 0/74 0% | 7/1809 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 9/2550 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 5/1592 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| B-Lymphoblastic Leukemia | 4/55 7% | 3/2640 0% |
| Other Solid Cancers | 0/94 0% | 4/1515 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 6/2534 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Head and Neck Carcinoma | 1/85 1% | 1/1574 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
| Breast Carcinoma | 0/144 0% | 3/3264 0% |
| Glioma | 0/52 0% | 2/2127 0% |
| Neuroblastoma | 1/87 1% | 0/1331 0% |
Mutation Distribution
Where IL27 is mutated · all tissues, split by cell line vs tissue
How many mutations in IL27 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 158 mutations in IL27
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|